Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,778,169
  • Shares Outstanding, K 170,495
  • Annual Sales, $ 1,072 M
  • Annual Income, $ 391,000 K
  • EBIT $ 105 M
  • EBITDA $ 111 M
  • 60-Month Beta 0.66
  • Price/Sales 3.56
  • Price/Cash Flow 25.25
  • Price/Book 3.09

Options Overview Details

View History
  • Implied Volatility 43.29% (-2.07%)
  • Historical Volatility 44.92%
  • IV Percentile 18%
  • IV Rank 9.66%
  • IV High 127.33% on 04/16/25
  • IV Low 34.30% on 03/19/25
  • Expected Move (DTE 11) 1.65 (7.44%)
  • Put/Call Vol Ratio 1.05
  • Today's Volume 76
  • Volume Avg (30-Day) 441
  • Put/Call OI Ratio 0.66
  • Today's Open Interest 12,903
  • Open Int (30-Day) 9,007
  • Expected Range 20.51 to 23.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.06
  • Number of Estimates 8
  • High Estimate 0.17
  • Low Estimate -0.04
  • Prior Year 0.11
  • Growth Rate Est. (year over year) -45.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.51 +3.02%
on 02/12/26
25.36 -12.62%
on 02/27/26
-1.40 (-5.94%)
since 02/06/26
3-Month
21.51 +3.02%
on 02/12/26
28.35 -21.83%
on 12/23/25
-5.28 (-19.24%)
since 12/05/25
52-Week
13.40 +65.37%
on 04/09/25
28.35 -21.83%
on 12/23/25
+4.55 (+25.84%)
since 03/06/25

Most Recent Stories

More News
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company’s Audit Committee...

ACAD : 22.16 (-1.07%)
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the company it has formally adopted...

ACAD : 22.16 (-1.07%)
Acadia: Q4 Earnings Snapshot

Acadia: Q4 Earnings Snapshot

ACAD : 22.16 (-1.07%)
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview

- Fourth quarter 2025 GAAP total revenues of $284 million and full year 2025 GAAP total revenues of $1.07 billion, reflecting 9% and 12% year-over-year growth, respectively ...

ACAD : 22.16 (-1.07%)
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: TD Cowen's 46th Annual Health Care Conference...

ACAD : 22.16 (-1.07%)
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

Company to host conference call and webcast on Wednesday, February 25, 2026, at 4:30 p.m. Eastern Time

ACAD : 22.16 (-1.07%)
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union

- Company expects to receive a negative opinion following oral explanation feedback and intends to request re‑examination upon review of formal adoption.

ACAD : 22.16 (-1.07%)
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

- 2028 projected combined net sales of approximately $1.7 billion including ~$1 billion for NUPLAZID ® and ~$700 million for DAYBUE ® - Top-line...

ACAD : 22.16 (-1.07%)
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive...

ACAD : 22.16 (-1.07%)
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome

-- DAYBUE STIX provides Rett syndrome patients and caregivers with new flexibility and choice in their treatment with DAYBUE -- DAYBUE and DAYBUE STIX are the only FDA-approved...

ACAD : 22.16 (-1.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations...

See More

Key Turning Points

3rd Resistance Point 23.12
2nd Resistance Point 22.71
1st Resistance Point 22.44
Last Price 22.16
1st Support Level 21.76
2nd Support Level 21.35
3rd Support Level 21.08

See More

52-Week High 28.35
Fibonacci 61.8% 22.64
Last Price 22.16
Fibonacci 50% 20.88
Fibonacci 38.2% 19.11
52-Week Low 13.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar